Genes & CellsGenes & CellsГены и КлеткиGenes and Cells2313-18292500-2562Human Stem Cells Institute12277810.23868/201906022ArticlesСтатьиReview ArticleKISS1/KISS1R SIGNAL SYSTEM AND ITS ROLE IN THE CARCINOGENESISСигнальная система KISS1/KISS1R и ее роль в канцерогенезеMnikhovichM. VМниховичМ. Вmnichmaxim@yandex.ruBezuglovaT. VБезугловаТ. ВKakturskyL. VКактурскийЛ. ВBunkovK. VБуньковК. ВTuchkovaA. SТучковаА. СTrifonovM. IТрифоновМ. ИMishinaE. SМишинаЕ. СFSBSIRI of Human MorphologyФГБНУ НИИ морфологии человекN.I. Pirogov RNRMUРНИМУ им. Н.И. ПироговаSmolensk Regional Institute of PathologyСмоленский областной институт патологииKursk State Medical University of the MH of RussiaКурский государственный медицинский университет МЗ России15092019143VOL 14, NO3 (2019)ТОМ 14, №3 (2019)12413017012023Copyright ©; 2019, Eco-VectorCopyright ©; 2019, Эко-Вектор2019Eco-VectorЭко-Векторhttps://genescells.ru/2313-1829/article/view/122778

The KISS1 / KISS1R signaling system can serve as a regulator of metastasis of tumors and is a potential prognostic marker of tumor processes. The action of kisspeptin10 on the Era-negative non - malignant breast epithelial cells or KISS1R expression in these cells can induce passage to the mesenchymal phenotype and to stimulate the invasiveness. The level of expression of KISS1 in remote breast cancer metastases is lower than in the primary tumor: methylation of the KISS1 promoter may be one of the reasons for the decrease of the expression of mRNA and KISS1 protein in the cells of breast cancer metastases in the brain. The clinical significance of KISS1 lies in the prediction of involvement in the neoplastic process in the lymphnodes. Features of expression of KISS1 / KISS1R in Era-positive tumors give hope for the emergence of new approaches to the treatment of these tumors. The level of KISS1 expression can serve as a molecular marker predicting the quality of tumor response to Tamoxifen therapy, especially in postmenopausal women.

Сигнальная система KISS1/KISS1R может служить регулятором метастазирования опухолей и является потенциальным прогностическим маркером опухолевых процессов. Воздействие кисспептина 10 на Era-отрицательные, не злокачественные, клетки эпителия молочной железы или синтез KISS1R в этих клетках могут индуцировать переход клеток к мезенхимальному фенотипу и стимулировать их инвазивность. Уровень экспрессии гена KISS1 в отдалённых метастазах рака молочной железы ниже, чем в первичной опухоли: метилирование промотора гена KISS1 может быть одной из причин снижения синтеза мрНК белка KISS1 в клетках метастазов рака молочной железы в головном мозге. Клиническая значимость белка KISS1 заключается в прогнозировании вовлечения в опухолевый процесс лимфоузлов. Особенности экспрессии KISS1/KISS1R в ERa-позитивных опухолях дают шанс на появление новых подходов лечения данных опухолей. Уровень синтеза KISS1 может служить молекулярным маркером, позволяющим предсказать качество ответа опухоли на терапию Тамоксифеном, особенно у женщин в постменопаузальном периоде.

KISS1RERaEGFRKISS1ERaEGFRoncomarkersbreast cancermetastasisepithelial-mesenchymal transitionКSS1онкомаркерырак молочной железыметастазыэпителиально-мезенхимальный переходMuir A.I., Chamberlain L., Elshourbagy N.A. et al. AXOR12, a novel human G protein-coupled receptor, activated by the peptide KiSS-1. J. Biol. Chem. 2001; 276: 28969-75.Ohtaki T., Shintani Y., Honda S. et al. Metastasis suppressor gene KiSS-1 encodes peptide ligand of a G-protein-coupled receptor. Nature 2001; 411: 613-7.Kostadima L., Pentheroudakis G., Pavlidis N. The missing KiSS of life: tran-scriptional activity of the metastasis suppressor gene KiSS-1 in early breast cancer. Anticancer Res. 2007; 27: 2499-504.Shengbing Z., Feng L.J., Bin W. et al. Expression of KiSS-1 gene and its role in invasion and metastasis of human hepatocellular carcinoma. Anat. Rec. 2009; 292: 1128-34.Ulasov I.V., Kaverina N.V., Pytel P. et al. Clinical significance of KISS-1 protein expression for brain invasion and metastasis. Cancer 2012; 118: 2096-105.Gonzalez C. Deepening on Breast Cancer Metastasis: The ER-Mediated Modulation of KISS/KISS1R System. Endocrinology 2013; 154(6): 1959-61.Tiana J., Al-Odainia A.A., Wangb Y. et al. KiSS1 gene as a novel mediator of TGFp-mediated cell invasion in triple negative breast cancer. Cellular Signalling 2018; 42: 1-10.Cvetkovic D., Dragan M., Leith S.J. et al. KIS1R induces invasiveness of estrogen receptor-negative human mammary epitelial and breast cancer cells. Endocrinology 2013; 154(6): 1999-2014.Miller W.R., Forrest P.M. Oestradiol synthesis by a human breast carcinoma. The Lancet 1974; 2(7885): 866-89.Yoshida B.A., Sokoloff M., Welch D.R. et al. Metastasis-suppressor genes: a review and perspective on an emerging field. J. Nat. Cancer 2000; 91(21): 1717-30.Stathakia M., Stamatioua M.E., Magiorisaet G. et al. The role of kis-speptin system in cancer biology. Critical Reviews in Oncology/Hematology 2019; 142: 130-40.Eccles S.A., Welch D.R. Metastasis: recent discoveries and novel treatment. Lancet 2007; 369: 1742-57.Slack B.E. The m3 muscarinic acetylcholine receptor is coupled to mitogenactivated protein kinase via protein kinase C and epidermal growth factor receptor kinase. Biochem. J. 2000; 348(2): 381-7.Krupnick J.G., Benovic J.L. The role of receptor kinases and arres-tins in G protein-coupled receptor regulation. Annu. Rev. Pharmacol. Toxicol. 1998; 38: 289-319.Kotani M., Detheux M., Vandenbogaerde A. et al. The metastasis suppressor gene KiSS-1 encodes kisspeptins, the natural ligands of the orphan G protein-coupled receptor GPR54. The Journal of biological chemistry 2001; 276(37): 34631-6.Gutierrez-Pascual E., Leprince J., Martinez-Fuentes A.J. et al. In vivo and in vitro structure-activity relationships and structural conformation of Kisspeptin-10-related peptides. Mol. Pharmacol. 2009; 76(1): 58-67.Pampillo M., Camuso N., Taylor J.E. et al. Regulation of GPR54 signaling by GRK2 and (betaj-arrestin. Mol. Endocrinol. 2009; 23(12): 2060-74.Goodman O.B., Jr., Krupnick J.G., Santini F. et al. Beta-arrestin acts as a clathrin adaptor in endocytosis of the beta2-adrenergic receptor. Nature 1996; 383: 447-50.Laporte S.A., Miller W.E., Kim K.M. et al. Beta-arrestin/AP-2 interaction in G proteincoupled receptor internalization: identification of a betaar-restin binging site in beta 2-adaptin. J. Biol. Chem. 2002; 277: 9247-54.Попова Н.В., Деев И.Е., Петренко А.Г. Клатринзависимый эндоцитоз и белки-адаптеры. Acta naturae 2013; 5(3): 66-77.Calebiro D., Nikolaev V.O., Persani L. et. al. Signaling by internalized G-protein-coupled receptors. Trends Pharmacol. Sci. 2010; 31: 221-8.Freedman N.J., Lefkowitz R.J. Desensitization of G protein-coupled receptors. Recent Prog. Horm. Res. 1996; 51: 319-51.Zajac M., Law J., Cvetkovic D.D. et al. GPR54 (KISS1R) transactivate EGFR to promote breast cancer cell invasiveness. PLoS One 2011; 6(6): e21599.Thomas S.M., Bhola N.E., Zhang Q. et al. Cross-talk between G protein-coupled receptor and epidermal growth factor receptor signaling pathways contributes to growth and invasion of head and neck squamous cell carcinoma. Cancer Res. 2006; 66(24): 11831-9.Clarke R.B., Anderson E., Howell A. Steroid receptors in human breast cancer. Trends Endocrinol. Metab. 2004; 15(7): 316-23.Miller W.R., O'Neill J.S. The importance of local synthesis of estrogen within the breast. Steroids 1987; 50(4-6): 537-47.Stingl J. Estrogen and progesterone in normal mammary gland development and in cancer. Horm. Cancer 2011; 2: 85-90.Carey L.A., Perou C.M., Livasy C.A. et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006; 295: 2492-502.Schiff R., Osborne C.K., Fuqua S.A. Clinical aspects of estrogen and progesterone receptors. In: Harris J.R., Lippman M.E., Morrow M. et al. editors. Diseases of the Breast. 4th ed. Philadelphia: Wolters Kluwer/Lip-pincottWilliams & Wilkins; 2009. p. 408-30.Key T.J. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. Journal of the National Cancer Institute 2002; 94(8): 606-16.Huijbregts L., de Roux N. KISS1 is down-regulated by 17beta-estradiol in MDA-MB-231 cells through a nonclassical mechanism and loss of ribonucleic acid polymerase II binding at the proximal promoter. Endocrinology 2010; 151: 3764-72.Klinge С.М. Estrogen receptor interaction with estrogen response elements. Nucleic Acids Research 2001; 29(14): 2905-19.Schiff R., Massarweh S.A., Shou J. et al. Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. Clin. Cancer Res. 2004; 10(1): 331-6.Marot D., Bieche I., Aumas C. et al. High tumoral levels of Kiss1 and G-protein-coupled receptor 54 expression are correlated with poor prognosis of estrogen receptor-positive breast tumors. Endocr. Relat. Cancer 2007; 14: 691-702.Massarweh S., Osborne C.K., Creighton C.J. Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res. 2008; 68: 826-33.Yarden R.I., Wilson M.A., Chrysogelos S.A. Estrogen suppression of EGFR expression in breast cancer cells: a possible mechanism to modulate growth. J. Cell. Biochem. Suppl. 2001; 36: 232-46.Guan-Zhen Y., Ying C., Can-Rong N. et al. Reduced protein expression of metastasis-related genes (nm23, KISS1, KAI1 and p53) in lymph node and liver metastases of gastric cancer. Int. J. Exp. Pathol. 2007; 88: 175-83.Pineda R., Garcia-Galiano D., Roseweir A. et al. Critical roles of kiss-peptins in female puberty and preovulatory gonadotropin surges as revealed by a novel antagonist. Endocrinology 2009; 151: 722-30.Kirby H.R., Maguire J.J., Colledge W.H. et al. International Union of Basic and Clinical Pharmacology. LXXVII. Kisspeptin receptor nomenclature, distribution, and function. Pharmacol. Rev. 2010; 62: 565-78.Platonov M.E., Borovjagin A.V., Kaverina N. et al. KISS1 tumor suppressor restricts angiogenesis of breast cancer brain metastases and sensitizes them to oncolytic virotherapy in vitro. Cancer Lett. 2018; 417: 75-88.Lurje G., Lenz H.J. EGFR signaling and drug discovery. Oncology 2009; 77(6): 400-10.Mitchell D.C., Stafford L.J., Li D. et al. Transcriptional regulation of KiSS-1 gene expression in metastatic melanoma by specificity protein-1 and its coactivator DRIP-130. Oncogene 2007; 26: 1739-47.Maguire J.J., Kirby H.R., Mead E.J. et al. Inotropic action of the puberty hormone kisspeptin in rat, mouse and human: cardiovascular distribution and characteristics of the kisspeptin receptor. PloS One 2011; 6(11): e27601.Shida D., Fang X., Kordula T. et al. Cross-talk between LPA1 and epidermal growth factor receptors mediates up-regulation of sphingosine kinase 1 to promote gastric cancer cell motility and invasion. Cancer Res. 2008; 68: 6569-77.Kasina S., Scherle P.A., Hall C.L. et al. ADAM-mediated amphiregulin shedding and EGFR transactivation. Cell Prolif. 2009; 42: 799-812.Cvetkovic D., Babwah A.V., Bhattacharya M. Kisspeptin/KISS1 R system in breast cancer. J. Cancer 2013; 4(8): 653-61.Briggs M.W., Sacks D.B. IQGAP proteins are integral components of cytoskeletal regulation. EMBO Rep. 2003; 4: 571-4.de Roux N., Genin E., Carel J.C. Hypogonadotropic hypogonadism due to loss of function of the KiSS1-derived peptide receptor GPR54. PNAS USA 2003; 100(19): 10972-6.Teng Y., Liu M., Cowell J.K. Functional interrelationship between the WASF3 and KISS1 metastasis-associated genes in breast cancer cells. Int. J. Cancer 2011; 129: 2825-35.Teng Y., Ren M.Q., Cheney R. et al. Inactivation of the WASF3 gene in prostate cancer cells leads to suppression of tumorigenicity and metastases. Br. J. Cancer 2010; 103: 1066-75.Shirasaki F., Takata M., Hatta N. et al. Loss of expression of metastasis suppressor gene KISS1 during melanoma progression and its association with lOh of chromosome 6q16.3-q23. Cancer Res. 2001; 61: 7422-5.Sanchez-Carbayo M., Capodieci P., Cordon-Cardo C. Tumor suppressor role of KiSS-1 in bladder cancer: loss of KiSS-1 expression is associated with bladder cancer progression and clinical outcome. Am. J. Pathol. 2003; 162(2): 609-17.Kostadima L., Pentheroudakis G., Pavlidis N. The missing kiss of life: transcriptional activity of the metastasis suppressor gene KiSS1 in early breast cancer. Anticancer Res. 2007; 27: 2499-504.Каверина Н.В., Уласов И.В., Фаворская И.А. и др. Влияние метилирования промотора kiss1 на подавление экспрессии гена в клетках рака молочной железы и его метастазов в головном мозге. Вестник РОНЦ им. Н.Н. Блохина РАМН 2011; 22(4): 17-23.Song W.W., Gui A.P., Li W. et al. Expressions of HIF-1a and KISS-1 in patients with liver cancer and correlation analysis. European Review for Medical and Pharmacological Sciences 2017; 21: 4058-63.Dhar D.K., Naora H., Kubota H. et al. Downregulation of KiSS-1 expression is responsible for tumor invasion and worse prognosis in gastric carcinoma. Int. J. Cancer 2004; 111: 868-72.Cho S.G., Yi Z., Pang X. et al. Kisspeptin-10, a KISS1-derived deca-peptide, inhibits tumor angiogenesis by suppressing Sp1-mediated VEGF expression and FAK/Rho GTPase activation. Cancer research 2009; 69: 7062-70.Chakraborty A., Basak J., Mukhopadhyay A. The Role of Kisspeptins (KiSS-1) in Breast Cancer Therapy: the Essential Kiss of Life. ARC Journal of Cancer Science 2016; 2(1): 1-3.Wang J., Gildea J.J., Yue W. Aromatase overexpression induces malignant changes in estrogen receptor alpha negative MCF-10A cells. Oncogene 2013; 32(44): 5233-40.Hugo H., Ackland M.L., Blick T. et al. Epithelial--mesenchymal and mesenchymal-epithelial transitions in carcinoma progression. J. Cell. Physiol. 2007; 213(2): 374-83.